Company insight Redefining development
The global healthcare industry is undergoing significant transformation as geopolitical shifts, economic pressures and regulatory changes reshape how pharmaceutical and medical device companies develop, manufacture and distribute products. By partnering with CDMOs like the Sanner Group, medtech innovators can create the basis for long-term growth – across borders and from development to design transfer and production.
everal macro trends are currently driving change in the pharmaceutical and medtech industries. Ageing populations, rising rates of chronic disease and the expansion of biologics are increasing demand for advanced drug delivery systems and medical devices. At the same time, the line between consumer products and medical technologies is blurring, placing greater emphasis on usability, patient experience and product design as key competitive differentiators. Another defining shift is the growing reliance on outsourcing. Pharmaceutical and biotech companies are increasingly partnering with external providers for integrated services spanning early-stage design, development, industrialisation and commercial manufacturing. In this environment, speed, flexibility and regulatory expertise have become critical advantages. While these changes are global, they are unfolding differently across regions, increasing the need for partners who think globally while acting locally.
S
Differences between the US and Europe
In the US, policy priorities are increasingly focused on domestic manufacturing. Government incentives, tariffs and investment programmes are encouraging companies to reshore critical production capacity. At the same time, healthcare affordability has become a major issue, placing increasing pressure on drug pricing. Moreover, new direct-to-consumer (DTC) platforms and programmes are emerging, particularly in fast-growing markets such as weight-management therapies. This trend is reshaping supply chains, marketing strategies and packaging. Meanwhile, the EU faces a complex balancing act. Policymakers must maintain access to the US market, tackle price increases for raw materials, ensure regulatory oversight for public health and protect domestic industries from lower- cost international competitors. These dynamics are extending pricing pressures
42
Sanner Group is a worldwide leader in medical device development, pharmaceutical and nutraceutical packaging, trusted for decades for its expertise in injection moulding and desiccant integration.
beyond pharmaceuticals to the broader healthcare supply chain.
A common challenge: finding the right partner For medical device companies all over the world, current developments require strategic adaptation. Supply chain resilience is becoming a critical differentiator, with companies adopting nearshoring, dual sourcing and regionalised production networks to reduce risk and improve agility. Moreover, regulatory expertise has also become a key value driver. Increasing regulatory complexity, such as the EU Medical Device Regulation and evolving US requirements for combination products, means that partners capable of guiding products from concept through approval are increasingly valuable. In this environment, growth depends on collaboration and forward-looking investment. Strategic partnerships, targeted acquisitions and innovation in areas such as wearable injectables, neurostimulation and smart drug delivery systems will shape the next generation of healthcare technologies. Companies that anticipate geopolitical and regulatory shifts and align innovation
with real-world economic constraints will be best positioned to help bring new therapies to patients faster, more safely and more efficiently.
Global expertise with local presence
Following its recent acquisitions of design and development specialists Gilero and Springboard, Sanner Group delivers fully integrated, single-source CDMO support for pharmaceutical and medtech companies – from device design and development to design transfer and global production – across its sites in Europe, North America and Asia.
This local presence, backed by global expertise, ensures supply chain resilience and supports manufacturers of drug delivery systems, combination products, medical devices and diagnostics in bringing their products to market with precision and reliability. Following the approach ‘Precision Engineered. Seamlessly Delivered.’, Sanner is the ideal partner for successful pharma and medtech projects all over the world. ●
www.sanner-group.com
www.medicaldevice-developments.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100
